Therapeutic Efficacy of Boron Neutron Capture Therapy Mediated by Boron-rich Liposomes for Oral Cancer in the Hamster Cheek Pouch Model

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2014 Oct 29

PMID 25349432

Citations 21

Authors

Elisa M Heber

M Frederick Hawthorne

Peter J Kueffer

Marcela A Garabalino

Silvia I Thorp

Emiliano C C Pozzi

Andrea Monti Hughes

Charles A Maitz

Satish S Jalisatgi

David W Nigg

Paula Curotto

Veronica A Trivillin

Amanda E Schwint

Affiliations

Soon will be listed here.

Abstract

The application of boron neutron capture therapy (BNCT) mediated by liposomes containing (10)B-enriched polyhedral borane and carborane derivatives for the treatment of head and neck cancer in the hamster cheek pouch oral cancer model is presented. These liposomes are composed of an equimolar ratio of cholesterol and 1,2-distearoyl-sn-glycero-3-phosphocholine, incorporating K[nido-7-CH3(CH2)15-7,8-C2B9H11] (MAC) in the bilayer membrane while encapsulating the hydrophilic species Na3[ae-B20H17NH3] (TAC) in the aqueous core. Unilamellar liposomes with a mean diameter of 83 nm were administered i.v. in hamsters. After 48 h, the boron concentration in tumors was 67 ± 16 ppm whereas the precancerous tissue contained 11 ± 6 ppm, and the tumor/normal pouch tissue boron concentration ratio was 10:1. Neutron irradiation giving a 5-Gy dose to precancerous tissue (corresponding to 21 Gy in tumor) resulted in an overall tumor response (OR) of 70% after a 4-wk posttreatment period. In contrast, the beam-only protocol gave an OR rate of only 28%. Once-repeated BNCT treatment with readministration of liposomes at an interval of 4, 6, or 8 wk resulted in OR rates of 70-88%, of which the complete response ranged from 37% to 52%. Because of the good therapeutic outcome, it was possible to extend the follow-up of BNCT treatment groups to 16 wk after the first treatment. No radiotoxicity to normal tissue was observed. A salient advantage of these liposomes was that only mild mucositis was observed in dose-limiting precancerous tissue with a sustained tumor response of 70-88%.

Citing Articles

Cobaltabis(Dicarbollide) [-COSAN] for Boron Neutron Capture Therapy of Head and Neck Cancer: Biodistribution and Irradiation Studies in an Experimental Oral Cancer Model.

Palmieri M, Monti Hughes A, Trivillin V, Garabalino M, Ramos P, Thorp S Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39459007 PMC: 11510372. DOI: 10.3390/ph17101367.

Nanostructured boron agents for boron neutron capture therapy: a review of recent patents.

Zhang X, Lin Y, Hosmane N, Zhu Y Med Rev (2021). 2024; 3(5):425-443.

PMID: 38283251 PMC: 10811353. DOI: 10.1515/mr-2023-0013.

In Vivo Application of Carboranes for Boron Neutron Capture Therapy (BNCT): Structure, Formulation and Analytical Methods for Detection.

Marforio T, Carboni A, Calvaresi M Cancers (Basel). 2023; 15(20).

PMID: 37894311 PMC: 10605826. DOI: 10.3390/cancers15204944.

Nanoplatforms: The future of oral cancer treatment.

Senevirathna K, Jayawickrama S, Jayasinghe Y, Prabani K, Akshala K, Pradeep R Health Sci Rep. 2023; 6(8):e1471.

PMID: 37547360 PMC: 10397482. DOI: 10.1002/hsr2.1471.

Enhancement in the Therapeutic Efficacy of In Vivo BNCT Mediated by GB-10 with Electroporation in a Model of Oral Cancer.

Olaiz N, Monti Hughes A, Pozzi E, Thorp S, Curotto P, Trivillin V Cells. 2023; 12(9).

PMID: 37174642 PMC: 10177359. DOI: 10.3390/cells12091241.

References

Fang J, Nakamura H, Maeda H . The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2010; 63(3):136-51. DOI: 10.1016/j.addr.2010.04.009. View

Pozzi E, Cardoso J, Colombo L, Thorp S, Monti Hughes A, Molinari A . Boron neutron capture therapy (BNCT) for liver metastasis: therapeutic efficacy in an experimental model. Radiat Environ Biophys. 2012; 51(3):331-9. DOI: 10.1007/s00411-012-0419-8. View

Jain R . Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307(5706):58-62. DOI: 10.1126/science.1104819. View

Banquerigo M, Shelly K, Hawthorne M, Brahn E . Model studies directed toward the application of boron neutron capture therapy to rheumatoid arthritis: boron delivery by liposomes in rat collagen-induced arthritis. Proc Natl Acad Sci U S A. 1998; 95(5):2531-4. PMC: 19402. DOI: 10.1073/pnas.95.5.2531. View

Matsumura Y, Maeda H . A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46(12 Pt 1):6387-92. View

Feakes D, Shelly K, Knobler C, Hawthorne M . Na3[B20H17NH3]: synthesis and liposomal delivery to murine tumors. Proc Natl Acad Sci U S A. 1994; 91(8):3029-33. PMC: 43508. DOI: 10.1073/pnas.91.8.3029. View

Gonzalez S, Bonomi M, Santa Cruz G, Blaumann H, Calzetta Larrieu O, Menendez P . First BNCT treatment of a skin melanoma in Argentina: dosimetric analysis and clinical outcome. Appl Radiat Isot. 2004; 61(5):1101-5. DOI: 10.1016/j.apradiso.2004.05.060. View

Barth R, Vicente M, Harling O, Kiger 3rd W, Riley K, Binns P . Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol. 2012; 7:146. PMC: 3583064. DOI: 10.1186/1748-717X-7-146. View

Moon R, Grubbs C, Sporn M . Inhibition of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis by retinyl acetate. Cancer Res. 1976; 36(7 PT 2):2626-30. View

10.

Altieri S, Balzi M, Bortolussi S, Bruschi P, Ciani L, Clerici A . Carborane derivatives loaded into liposomes as efficient delivery systems for boron neutron capture therapy. J Med Chem. 2009; 52(23):7829-35. DOI: 10.1021/jm900763b. View

11.

Miller M, Quintana J, Ojeda J, Langan S, Thorp S, Pozzi E . New irradiation facility for biomedical applications at the RA-3 reactor thermal column. Appl Radiat Isot. 2009; 67(7-8 Suppl):S226-9. DOI: 10.1016/j.apradiso.2009.03.107. View

12.

Li T, Hamdi J, Hawthorne M . Unilamellar liposomes with enhanced boron content. Bioconjug Chem. 2006; 17(1):15-20. DOI: 10.1021/bc0501350. View

13.

Koganei H, Ueno M, Tachikawa S, Tasaki L, Ban H, Suzuki M . Development of high boron content liposomes and their promising antitumor effect for neutron capture therapy of cancers. Bioconjug Chem. 2012; 24(1):124-32. DOI: 10.1021/bc300527n. View

14.

Henriksson R, Capala J, Michanek A, Lindahl S, Salford L, Franzen L . Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol. 2008; 88(2):183-91. DOI: 10.1016/j.radonc.2006.04.015. View

15.

Perez M, Raimondi A, Itoiz M . An experimental model to demonstrate the carcinogenic action of oral chronic traumatic ulcer. J Oral Pathol Med. 2004; 34(1):17-22. DOI: 10.1111/j.1600-0714.2004.00249.x. View

16.

Eveson J . Animal models of intra-oral chemical carcinogenesis: a review. J Oral Pathol. 1981; 10(3):129-46. DOI: 10.1111/j.1600-0714.1981.tb01259.x. View

17.

Shklar G, Eisenberg E, Flynn E . Immunoenhancing agents and experimental leukoplakia and carcinoma of the hamster buccal pouch. Prog Exp Tumor Res. 1979; 24:269-82. DOI: 10.1159/000402104. View

18.

Molinari A, Pozzi E, Monti Hughes A, Heber E, Garabalino M, Thorp S . "Sequential" boron neutron capture therapy (BNCT): a novel approach to BNCT for the treatment of oral cancer in the hamster cheek pouch model. Radiat Res. 2011; 175(4):463-72. DOI: 10.1667/RR2148.1. View

19.

Garabalino M, Monti Hughes A, Molinari A, Heber E, Pozzi E, Cardoso J . Boron neutron capture therapy (BNCT) for the treatment of liver metastases: biodistribution studies of boron compounds in an experimental model. Radiat Environ Biophys. 2010; 50(1):199-207. DOI: 10.1007/s00411-010-0345-6. View

20.

Kreimann E, Itoiz M, Longhino J, Blaumann H, Calzetta O, Schwint A . Boron neutron capture therapy for the treatment of oral cancer in the hamster cheek pouch model. Cancer Res. 2001; 61(24):8638-42. View